Skip to main content
Premium Trial:

Request an Annual Quote

Bruker Expands License Agreement with 3M for Tissuetyper Tech

NEW YORK (GenomeWeb) – Bruker said today that it has expanded its license agreement with 3M for technology underlying its MALDI Tissuetyper platform.

According to Bruker, the expanded agreement will allow it to develop the platform for use in anatomical pathology laboratories, including for building clinically validated content libraries.

The MALDI Tissuetyper uses MALDI mass spec-based proteomic profiles to analyze formalin-fixed paraffin-embedded tissue sections and is intended as a complement to existing histology techniques. Bruker currently markets the platform for research use. The expanded global license will allow the company to market it for routine use.

Financial and other terms of the agreement were not disclosed.